13F HOLDINGS REPORT
Decheng Capital LLC
Quarter ended Q3 2024 · Filed November 15, 2024 · Accession 0001104659-24-119361
Total Value
$422.2M
Positions
26
Other Managers
0
Confidential Omitted
No
Holdings (26)
| # | Issuer | Ticker / CUSIP | Shares | Value | % of Filing |
|---|---|---|---|---|---|
| 1 | CG ONCOLOGY INC | CGON | 5,478,810 | $206.7M | 48.96% |
| 2 | Nuvation Bio Inc. | NUVB | 25,954,439 | $59.4M | 14.08% |
| 3 | PHATHOM PHARMACEUTICALS INC | PHAT | 1,250,000 | $22.6M | 5.35% |
| 4 | Arcus Biosciences, Inc | RCUS | 869,790 | $13.3M | 3.15% |
| 5 | KRYSTAL BIOTECH INC | KRYS | 71,772 | $13.1M | 3.09% |
| 6 | Illumnia, Inc. | ILMN | 94,767 | $12.4M | 2.93% |
| 7 | Zentalis Pharmaceuticals Inc. | ZNTL | 3,108,095 | $11.4M | 2.71% |
| 8 | BeyondSpring Inc. | BYSI | 4,958,143 | $11.4M | 2.69% |
| 9 | NEWAMSTERDAM PHARMA CO NV | NAMSW | 590,000 | $9.8M | 2.32% |
| 10 | MERUS NV | N5749R100 | 189,098 | $9.4M | 2.24% |
| 11 | MOONLAKE IMMUNOTHERAPEUTICS | MLTX | 166,600 | $8.4M | 1.99% |
| 12 | CRINETICS PHARMACEUTICALS IN | CRNX | 157,958 | $8.1M | 1.91% |
| 13 | LEGEND BIOTECH CORP-ADR | LEGN | 108,558 | $5.3M | 1.25% |
| 14 | CYTOKINETICS INC | CYTK | 94,043 | $5.0M | 1.18% |
| 15 | Aura Biosciences, Inc. | AURA | 515,555 | $4.6M | 1.09% |
| 16 | GeneDx Holdings Corp. | WGSWW | 103,604 | $4.4M | 1.04% |
| 17 | 4D MOLECULAR THERAPEUTICS IN | FDMT | 397,835 | $4.3M | 1.02% |
| 18 | Equillium Inc. | EQ | 4,447,308 | $3.7M | 0.88% |
| 19 | VERA THERAPEUTICS INC | VERA | 69,767 | $3.1M | 0.73% |
| 20 | LONGBOARD PHARMACEUTICALS IN | 54300N103 | 56,350 | $1.9M | 0.44% |
| 21 | ARCELLX INC | ACLX | 21,177 | $1.8M | 0.42% |
| 22 | Pyxis Oncology, Inc (formerly Apexigen) | PYXS | 326,810 | $1.2M | 0.28% |
| 23 | AtriCure Inc. | ATRC | 26,797 | $751,388 | 0.18% |
| 24 | GRAIL INC | GRAL | 9,684 | $133,252 | 0.03% |
| 25 | REVOLUTION MEDICINES INC(NSM) | RVMDW | 2,000 | $90,700 | 0.02% |
| 26 | Nuvation Bio Inc. | NUVB | 646,057 | $63,249 | 0.01% |